Post-marketing Experiences with Belimumab in the Treatment of SLE Patients

被引：17
作者：
Askanase, Anca D. [1 ]
Yazdany, Jinoos [2 ]
Molta, Charles T. [1 ,3 ]
机构：
[1] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA
[2] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
[3] GlaxoSmithKline, Philadelphia, PA 19112 USA
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2014年 / 40卷 / 03期
关键词：
SLE; Lupus; Belimumab; Observational studies; SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-LYMPHOCYTE STIMULATOR; MONOCLONAL-ANTIBODY; REVISED CRITERIA; DISEASE-ACTIVITY; DOUBLE-BLIND; CLASSIFICATION; PREVALENCE; SAFETY; TRIAL;
D O I：
10.1016/j.rdc.2014.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Belimumab (Benlysta) is a human recombinant monoclonal antibody that targets and inhibits soluble B-lymphocyte stimulator, also known as B-cell activating factor, a proliferation and survival factor for B cells. The published clinical trials data showed that in patients with active systemic lupus erythematosus (SLE), belimumab effectively reduced peripheral B-cell levels and improved disease activity. This article reviews the belimumab clinical trials and the post-marketing experience with belimumab in the treatment of those lupus patients with persistent active disease despite current standard of care (SOC) therapy.
引用
收藏
页码：507 / +
页数：12
相关论文
共 27 条
[1]  
Askanase A, 2013, ARTHRITIS RHEUM-US, V65, pS668
[2]   Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus [J].
Askanase, Anca D. ;
Wallace, Daniel J. ;
Weisman, Michael H. ;
Tseng, Chung-E ;
Bernstein, Lana ;
Belmont, H. Michael ;
Seidman, Ernest ;
Ishimori, Mariko ;
Izmirly, Peter M. ;
Buyon, Jill P. .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (01) :89-95
[3]   Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator [J].
Baker, KP ;
Edwards, BM ;
Main, SH ;
Choi, GH ;
Wager, RE ;
Halpern, WG ;
Lappin, PB ;
Riccobene, T ;
Abramian, D ;
Sekut, L ;
Sturm, B ;
Poortman, C ;
Minter, RR ;
Dobson, CL ;
Williams, E ;
Carmen, S ;
Smith, R ;
Roschke, V ;
Hilbert, DM ;
Vaughan, TJ ;
Albert, VR .
ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3253-3265
[4]   Belimumab in Systemic Lupus Erythematosus - What Can Be Learned from Longterm Observational Studies? [J].
Bengtsson, Anders A. .
JOURNAL OF RHEUMATOLOGY, 2014, 41 (02) :192-193
[5]  
Carneiro JRM, 1999, J RHEUMATOL, V26, P1275
[6]  
Collins CE, 2013, ARTHRITIS RHEUM-US, V65, pS738
[7]  
Fredericks C, 2014, LUPUS
[8]   Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus [J].
Furie, Richard ;
Stohl, William ;
Ginzler, Ellen M. ;
Becker, Michael ;
Mishra, Nilamadhab ;
Chatham, Winn ;
Merrill, Joan T. ;
Weinstein, Arthur ;
McCune, W. Joseph ;
Zhong, John ;
Cai, Wendy ;
Freimuth, William .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (05)
[9]   A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus [J].
Furie, Richard ;
Petri, Michelle ;
Zamani, Omid ;
Cervera, Ricard ;
Wallace, Daniel J. ;
Tegzova, Dana ;
Sanchez-Guerrero, Jorge ;
Schwarting, Andreas ;
Merrill, Joan T. ;
Chatham, W. Winn ;
Stohl, William ;
Ginzler, Ellen M. ;
Hough, Douglas R. ;
Zhong, Z. John ;
Freimuth, William ;
van Vollenhoven, Ronald F. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (12) :3918-3930
[10]   Novel Evidence-Based Systemic Lupus Erythematosus Responder Index [J].
Furie, Richard A. ;
Petri, Michelle A. ;
Wallace, Daniel J. ;
Ginzler, Ellen M. ;
Merrill, Joan T. ;
Stohl, William ;
Chatham, W. Winn ;
Strand, Vibeke ;
Weinstein, Arthur ;
Chevrier, Marc R. ;
Zhong, Z. John ;
Freimuth, William W. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (09) :1143-1151
123